Introduction {#Sec1}
============

The novel coronavirus infection initially breaks out in Wuhan, China, and, as of April 9, has spread to more than 200 countries and regions in the whole world. The disease caused by the novel coronavirus (SARS-CoV-2) is now named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). As of April 9, 2020, there are accumulative 1,436,198 confirmed cases and 85,522 deaths in the whole world, with an average mortality of about 6.0% \[[@CR1]\], which is lower than that of severe acute respiratory syndrome (SARS) \[[@CR2]\] and Middle East respiratory syndrome (MERS) \[[@CR3]\]. However, the mortality is extremely high in critically ill patients with COVID-19 (62%) \[[@CR4]\], and older patients with comorbidities are at increased risk of developing critical illness and death \[[@CR4]--[@CR6]\]. The severity of COVID-19 poses great strain on critical care resources in hospitals, especially when they are not adequately staffed or resourced \[[@CR4]\]. Therefore, stratifying the severity of older patients with or without comorbidities on admission is beneficial to allocate medical resources accordingly.

During the outbreak of COVID-19, in clinical practice, auscultation is limited to identify pulmonary lesions due to the isolation of protective clothing. Although radiation dose \[[@CR7], [@CR8]\] needs to be considered, chest CT as reported previously plays an important role in disease diagnosis, monitoring, severity stratification, and evaluation of treatment response in patients with COVID-19 \[[@CR9], [@CR10]\], which goes beyond the ability of reverse transcription polymerase chain reaction (RT-PCR).

In this single-center study, aiming to further identify the value of chest CT in clinical management of COVID-19, we evaluated the association of initial chest CT findings obtained at admission with severity and clinical outcomes in older patients with COVID-19.

Materials and methods {#Sec2}
=====================

Study cohort {#Sec3}
------------

This retrospective single-center study was approved by the Ethics Commission of Tongji Hospital and written informed consent was waived due to emergence of epidemic outbreak. Tongji Hospital is the largest general hospital in Wuhan and has been designated to take care the treatment of severe COVID-19 patients by the Chinese government since late January 2020. We retrospectively reviewed 2237 older (≥ 60 years old) patients with confirmed infection of SARS-CoV-2 and admitted to Tongji Hospital between January 21 and February 14, 2020. All patients were confirmed with positive results of RT-PCR in throat swab specimens. Of the 2237 patients, as of March 4, 2020, 212 died of COVID-19, 613 recovered and were discharged from the hospital, and other 1412 patients were still in hospitalization. We finally enrolled 98 patients (46 died patients and 52 survival patients) who had undergone chest CT scans before admitting to the hospital or within 24 h of admission (Fig. [1](#Fig1){ref-type="fig"}). We defined these CT scans as "initial CT" scans. The 52 survival patients were discharged before March 4, 2020, based on the criterion of the diagnosis and treatment program (trial 7th version) published by the National Health Commission of the People's Republic of China \[[@CR11]\]. The clinical characteristics of the 98 older patients were collected from electronic medical records. A CT score was calculated using chest CT for each patient. According to the prognosis, we divided the 98 patients into a survival group and a death group, and the CT scores were compared between the two groups.Fig. 1Flowchart showing the inclusion criteria of this study

CT technique and image interpretation {#Sec4}
-------------------------------------

Chest CT images were obtained using the protocol described in a previously reported study \[[@CR10]\]. Two certified radiologists (with 8 and 3 years of experience in interpreting thoracic imaging, respectively) were blinded to patient outcomes and reviewed all chest CT images by consensus.

CT findings were graded on a 3-point scale focused on predominant CT patterns and based on the classification system as previously described \[[@CR12]\]: 1, normal attenuation; 2, ground-glass opacity (GGO); 3, consolidation. Because this study was focused on evaluating the association between early CT features corresponding to diffuse alveolar damage at early stage and prognosis, Ichikado K's scale points 4, 5, and 6 \[[@CR12]\], which are associated with the late proliferative or fibrotic phase, were not used. GGO was defined as increasing density of attenuation that did not conceal the underlying vessels. Consolidation was defined as increasing density of attenuation that concealed vessels.

In addition, the severity of each lung lobe (left upper/lower lobe and right upper/middle/lower lobe) was scored on the basis of predominant lesion extent in the corresponding lobe, as 0 (0%), 1 (1--25%), 2 (26--50%), 3 (51--75%), and 4 (76--100%) \[[@CR13]\]. The 4-point scale of severity of lung lobe was multiplied by the 3-point scale of CT findings, generating an overall score termed as "CT score." The CT score of each lobe ranged from 0 to 12, and the finally obtained total cumulative score values of all lung lobes ranged from 0 to 60.

In the survival (*n* = 52) and death (*n* = 46) groups, the patients were sub-grouped based on the time interval between symptom onset and the "initial CT" scan: subgroup1 (interval ≤ 5 days), subgroup2 (interval between 6 and 10 days), and subgroup3 (interval \> 10 days).

Statistical analysis {#Sec5}
--------------------

The software SPSS (IBM SPSS Statistics, version 20.0.0), GraphPad Prism (version 7.00), and R (RStudio, version 1.2.5033) were used for statistical analysis. Continuous variables were expressed as mean ± standard deviation (SD) or median and interquartile range (IQR). Categorical variables were reported as counts and frequencies in each category. The proportion rates of clinical characteristics in the two groups were compared by the chi-square test.

The mean CT scores of the "initial CT" on admission between the survival group and death group in total, and on the basis of each subgroup, were compared by Student's *t* test. A receiver operating characteristic (ROC) curve with an area under the ROC curve (AUC) was used to analyze the performance of "initial CT" in predicting outcomes, and an optimal cutoff value with maximum sensitivity and specificity was obtained. Adjusted ROC curve was applied to exclude the influence of confounding factors of age and gender. *p* value less than 0.05 (two-tailed) was considered statistically significant.

Results {#Sec6}
=======

General information {#Sec7}
-------------------

Epidemiologically, in our retrospective cohort, all 98 patients (mean age, 71.1 ± 8.5 years old; 66.3% are men) were local residents of Wuhan City; 2 patients acknowledged a history of contact with Wuhan's Huanan seafood market; 2 patients had familial cluster exposure; and 1 patient was a medical staff. There was no significant difference in age distribution between the death group and survival group (72.7 ± 8.9 vs 69.7 ± 8.0, *p* = 0.074). The proportion of men was significantly higher in the death group than the survival group (78.3% vs 55.8%, *p* = 0.019) (Table [1](#Tab1){ref-type="table"}). In total, 67/98 (68.4%) patients were having comorbidities and 46/98 (46.9%) suffered from hypertension. In reviewed comorbidities, the proportion rate of chronic renal disease in the death group was statistically higher (*p* = 0.027) than that in the survival group. The median time interval of symptom onset to "initial CT" scan was 7 days (IQR, 3.75--10). There was no significant difference (*p* = 0.142) in the time interval of symptom onset and "initial CT" scan on admission between the two groups. The median hospital stay in the survival group was significantly longer than that in the death group (24 days vs 7.0 days, *p* \< 0.001).Table 1Demographic and clinical characteristics of patients in the death and survival groupsCharacteristicsAll patients (*n* = 98)Death (*n* = 46)Survival (*n* = 52)*p* value\*Age  Mean ± SD (year)71.1 ± 8.572.7 ± 8.969.7 ± 8.00.074  Range (year)60--9560--9561--92Sex  Male65 (66.3%)36 (78.3%)29 (55.8%)0.019  Female33 (33.7%)10 (21.7%)23 (44.2%)History of exposure  Familial cluster 2 (2.0%) 0 2 (3.8%)0.179  Medical staff 1 (1.0%) 0 1 (1.9%)0.344  Huanan market 2 (2.0%) 0 2 (3.8%)0.179Symptoms  Fever78 (79.6%)35 (76.1%)43 (82.7%)0.418  Cough44 (44.9%)25 (54.3%)19 (36.5%)0.077  Dyspnea17 (17.3%)13 (28.3%) 4 (7.7%)0.007  Chest tightness 9 (9.2%) 7 (15.2%) 2 (3.8%)0.052  Fatigue and poor appetite21 (21.4%)11 (23.9%)10 (19.2%)0.573  Diarrhea11 (11.2%) 7 (15.2%) 4 (7.7%)0.239  Rhinorrhea 0 1 (1.9%)0.344Comorbidities  Hypertension46 (46.9%)21 (45.7%)25 (48.1%)0.810  Type 2 diabetes14 (14.3%) 5 (10.9%) 9 (17.3%)0.363  Coronary heart disease15 (15.3%) 9 (19.6%) 6 (11.5%)0.271  COPD 7 (7.1%) 5 (10.9%) 2 (3.8%)0.178  Postoperative lung cancer 2 (2.0%) 1 (2.2%) 1 (1.9%)0.930  Chronic renal disease10 (10.2%) 8 (17.4%) 2 (3.8%)0.027  Chronic hepatitis 2 (2.0%) 2 (4.3%) 00.129  None31 (31.6%)13 (28.3%)18 (34.6%)0.500Symptom onset before CT, median (IQR) (days) 7 (3.75--10) 6 (2.75--10) 8 (4--11)0.142Hospital stay, median (IQR) (days)16.5 (7.75--25) 7 (3--11)24 (19--29)\< 0.001\*Between death group and survival group*COPD*, chronic obstructive pulmonary disease

Clinical symptoms and treatments {#Sec8}
--------------------------------

The most common clinical manifestations of patients in this study were fever (78/98 \[79.6%\]) and cough (44/98 \[44.9%\]). The proportion of dyspnea in the death group was significantly higher than that in the survival group (*p* = 0.007). There was no significant difference for other symptoms like fever, cough, chest tightness, weakness, and diarrhea.

All 98 patients received isolation and antiviral agents and oxygen therapy (including nasal oxygen breath and mask oxygen inhalation). Most patients (80%) were empirically treated with antibiotics and glucocorticoids. Some patients (30%) also received immunoglobulin treatment. In the death group, 19/46 (41.3%) of patients required non-invasive mechanical ventilation, 14/46(30.4%) patients required invasive mechanical ventilation, and 1 patient required extracorporeal membrane oxygenation (ECMO) treatment. In the survival group, 1 patient required non-invasive mechanical ventilation, and no patients received invasive mechanical ventilation or ECMO.

Chest CT evaluation {#Sec9}
-------------------

Of the 98 patients, 84 underwent chest CT scans before admission, and 14 underwent CT scans within 24 h after admission. According to the subgrouping rules mentioned earlier, in the death group, there were 24 patients in subgroup1, 16 patients in subgroup2, and 6 patients in subgroup3. In the survival group, there were 22 patients in subgroup1, 17 patients in subgroup2, and 13 patients in subgroup3.

GGO and consolidation are two main signs of COVID-19 lesions on chest CT images with or without vascular enlargement, interlobular septal thickening, air bronchogram sign, and air trapping, and the lesions were predominantly peripheral and subpleural. On CT images, 35 of the total 260 lobes were not involved in patients of the survival group, and 8 of the total 230 lobes were not involved in patients of the death group. A total of 53.2% (118/222) lobes involved in the death group and 32% (72/225) lobes involved in the survival group showed predominantly consolidation. Consolidations on CT images were more common in the death group than in the survival group (*p* \< 0.001) (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). Pleural effusion was found in CT images of 2 patients in the death group. No mediastinal lymphadenopathy was seen on chest CT images.Fig. 2A 61-year-old male with COVID-19 in the death group. **a**, **c** Transverse and coronal CT images with score of 2 (1 \[1--25%\] \* 2 \[GGO\]) showed GGO (white arrow) in the right lower lobe when the patient underwent CT scan on the same day with fever onsets. **b**, **d** Transverse and coronal CT images with score of 40 (calculated as 3 \[50--75% distribution in right upper lobe\] \* 2 \[GGO, black arrow head\] + 3 \[50--75% distribution in left upper lobe\] \* 2 \[GGO, black arrow head\] + 4 \[\> 75% distribution in right lower lobe\] \* 3 \[consolidation, black arrow\] + 4 \[\> 75% distribution in left lower lobe\] \* 3 \[consolidation, black arrow\] + 2 \[GGO, not showed\] \* 2 \[25--50% distribution in right middle lobe\]) showed lesions in whole lung lobes 9 days after onset (10 days before death)Fig. 3A 66-year-old female with COVID-19 in the survival group who caught a fever on February 18, 2020, and admitted at the hospital on February 28, 2020. **a** On February 23, transverse CT with score of 10 showed GGO in the right middle lobe and consolidation in both lower lobes. **b** On February 27, transverse CT with score of 24 showed increased consolidation, which was defined as "initial CT" according to the rules in this study

The mean CT score was significantly higher in the death group than in the survival group (34.5 ± 15.0 vs 18.6 ± 11.3, *p* \< 0.001). For subgroup1 and subgroup2, a higher mean CT score was found for the death group (33.0 ± 17.1 vs 12.9 ± 8.7, *p* \< 0.001; 38.8 ± 12.3 vs 24.3 ± 11.9, *p* = 0.002, respectively) and no significant difference of CT score was identified with respect to subgroup3 (28.8 ± 11.5 vs 20.7 ± 10.4, *p* = 0.144) (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4CT scores of different subgroups in the death and survival groups. (In the survival or death group, patients were sub-grouped based on the interval time between symptom onset and the initial CT scan: subgroup1 (interval ≤ 5 days after symptom onset), subgroup2 (interval between 6 and 10 days), and subgroup3 (interval \> 10 days)

From ROC curve analysis, in subgroup1, CT score of 14.5 with a sensitivity of 83.3% and a specificity of 77.3% for the prediction of mortality was an optimal cutoff value, with an area under the curve (AUC) of 0.875 (95% CI 0.778--0.972) and adjusted AUC of 0.881 (95% CI 0.789--0.976). In subgroup2, CT score of 27.5 with a sensitivity of 87.5% and a specificity of 70.6% for the prediction of mortality was an optimal cutoff value, with an AUC of 0.814 (95% CI 0.660--0.969) and adjusted AUC of 0.895 (95% CI 0.677--0.977) (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5ROC curve analysis of the CT scores including crude ROC curve and adjusted ROC curve after the adjustment for age and gender in the full cohort and in subgroup1, subgroup2, and subgroup3 for prediction of mortality

Discussion {#Sec10}
==========

In clinical practice, clinicians with isolation of protective clothing cannot auscultate and no frequent CT scans are performed for patients with COVID-19. Thus, using information of "initial CT" scan on admission to assess and predict severity of the disease is useful and valuable for planning treatment strategies and evaluating prognosis. In this study, the CT score calculated from the "initial CT" scan can effectively predict mortality in older patients with COVID-19, showing a sensitivity of 83.3%, a specificity of 77.3%, and an adjusted AUC value of 0.881 (cutoff is 14.5), when the "initial CT" scans were done within 5 days after symptom onsets; the corresponding performance changes to a sensitivity of 87.5%, a specificity of 70.6%, and an adjusted AUC of 0.895 (cutoff is 27.5) when the time interval was 6 to 10 days between symptom onsets and CT scan.

From previous studies, it has been shown that older age, gender of male, and co-existing comorbidities might be risk factors for the poor prognosis of COVID-19 patients \[[@CR4]--[@CR6], [@CR14]\]. In this single-center study on older patients, the proportion of men was significantly higher in the death group than in the survival group (*p* = 0.019), which was consistent with what was observed in a previous study \[[@CR15]\]. However, it is important to notice that there was no significant difference in age distribution between the death group and survival group. In total, the proportion of severe symptom onsets (dyspnea) and co-existence with chronic renal disease was higher in the death group than in the survival group.

Two main CT signs of COVID-19 lesions are GGO and consolidation, which are similar to the CT features for SARS and MERS, and the lesions were predominantly peripheral and subpleural, consistent with previous studies \[[@CR9], [@CR10], [@CR13], [@CR14], [@CR16], [@CR17]\]. Consolidations were more common in the death group than in the survival group. These CT findings may correspond to viscous secretions seeping through the pulmonary alveoli described in the autopsy report \[[@CR18]\] and suggest acute respiratory distress syndrome (ARDS). ARDS characterized by an acute, diffuse, inflammatory lung injury, leading to an increased alveolar capillary permeability, is a strong predictor of mortality, reflecting the severity of respiratory failures \[[@CR19]\]. Our results supported the investigation that chest CT is possible to predict clinical course of ARDS \[[@CR12], [@CR20]\].

In this study, the overall CT score was based on the severity of air-space abnormality and its distribution. The mean CT score of chest CT images in the death group was significantly higher than that in the survival group. However, as previously reported \[[@CR14]\], serial CT showed disease changes, and the most common pattern of evolution was initial progression to a peak level, followed by improvement. Our results showed that the "initial CT" score changes with respect to different time intervals between symptom onsets and CT scans. In subgroup1 and subgroup2, patients underwent CT scans within 10 days after symptom onsets, where the mean score of "initial CT" was statistically higher in the death group than in the survival group. This suggests that severe manifestation on CT at an early stage may indicate poor prognosis. In subgroup3, the time interval between symptom onsets and "initial CT" was longer than 10 days, where no significant difference was identified between the death group and survival group. According to Fig. [4](#Fig4){ref-type="fig"}, in either the death or survival group, CT score of chest CT in subgroup2 was higher (though not statistically significant) than that in subgroup1 and subgroup3. This may indicate a progression course of 6--10 days after symptom onsets. However, this finding needs further evaluation.

This study had several limitations. First, we compared the scores of "initial CT" between the death and survival groups in terms of 3 subgroups, which does not account for individual variations. Second, due to the popularity of RT-PCR, many patients would not undergo CT scans for diagnosis before admission; thus, our study only included a relatively small number of cases who had initial CT scans acquired. Third, the CT scores were evaluated on the consensus of two readers rather than an independent reading, and there was a lack of assessment on the inter-observer agreement. Fourth, because of the retrospective nature of the study, there is an inclusion bias, though we tried to avoid and such inclusion bias is inevitable, and our results should be carefully interpreted.

In summary, in this single-center study, we observed the prognosis implication of chest CT scores calculated by determining the extents of GGO and consolidation. We found that "initial CT" scores may be useful to stratify patients, which has a potentially important utility in the current global medical situation, especially for rational allocation of medical resources. However, a clear identification of the time interval between symptom onsets and "initial CT" is crucial. Further studies may include evaluation on a larger cohort and exploring the effects of this semi-quantitative method in monitoring disease progression and in assessing treatment responses.
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